S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Fate Therapeutics (FATE) Earnings Date, Estimates & Call Transcripts

$4.79
-0.25 (-4.96%)
(As of 04/19/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 1Estimated
Actual EPS
(Feb. 26)
-$0.45 Beat By $0.12
Consensus EPS
(Feb. 26)
-$0.57
Skip Charts & View Estimated and Actual Earnings Data

FATE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

FATE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Fate Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243($0.58)($0.46)($0.51)
Q2 20243($0.59)($0.38)($0.48)
Q3 20243($0.61)($0.39)($0.49)
Q4 20243($0.49)($0.40)($0.45)
FY 202412($2.27)($1.63)($1.93)

FATE Earnings Date and Information

Fate Therapeutics last posted its earnings data on February 26th, 2024. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.12. The business earned $1.68 million during the quarter, compared to analysts' expectations of $0.85 million. Fate Therapeutics has generated ($1.64) earnings per share over the last year (($1.64) diluted earnings per share). Earnings for Fate Therapeutics are expected to grow in the coming year, from ($1.94) to ($1.84) per share. Fate Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based off prior year's report dates.

Fate Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/1/2024
Estimated)
------- 
2/26/2024Q4 2023($0.57)($0.45)+$0.12($0.45)$0.85 million$1.68 million    
11/8/2023Q3 2023($0.59)($0.46)+$0.13($0.46)$0.99 million$1.94 million
8/8/2023Q2 2023($0.58)($0.54)+$0.04($0.54)$5.41 million$0.93 million    
5/3/2023Q1 2023($0.55)($0.19)+$0.36($0.19)$33.53 million$58.98 million    
2/28/2023Q4 2022($0.86)($0.58)+$0.28($0.58)$18.41 million$44.36 million    
11/3/2022Q3 2022($0.93)($0.86)+$0.07($0.86)$15.34 million$14.98 million
8/3/2022Q2 2022($0.86)($0.79)+$0.07($0.79)$13.42 million$18.55 million
5/4/2022Q1 2022($0.78)($0.68)+$0.10($0.68)$9.01 million$18.40 million    
2/28/2022Q4 2021($0.68)($0.72)($0.04)($0.72)$11.55 million$17.10 million    
11/4/2021Q3 2021($0.58)($0.45)+$0.13($0.69)$8.67 million$14.23 million    
8/4/2021Q2 2021($0.52)($0.58)($0.06)($0.58)$6.90 million$13.41 million    
5/5/2021Q1 2021($0.42)($0.48)($0.06)($0.48)$7.07 million$11.14 million  

Fate Therapeutics Earnings - Frequently Asked Questions

When is Fate Therapeutics's earnings date?

Fate Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based off last year's report dates. Learn more on FATE's earnings history.

Did Fate Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Fate Therapeutics (NASDAQ:FATE) reported ($0.45) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.57) by $0.12. Learn more on analysts' earnings estimate vs. FATE's actual earnings.

How can I listen to Fate Therapeutics's earnings conference call?

The conference call for Fate Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Fate Therapeutics's conference call transcript?

The conference call transcript for Fate Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Fate Therapeutics generate each year?

Fate Therapeutics (NASDAQ:FATE) has a recorded annual revenue of $63.53 million.

How much profit does Fate Therapeutics generate each year?

Fate Therapeutics (NASDAQ:FATE) has a recorded net income of -$160.93 million. FATE has generated -$1.64 earnings per share over the last four quarters.

What is Fate Therapeutics's EPS forecast for next year?

Fate Therapeutics's earnings are expected to grow from ($1.94) per share to ($1.84) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:FATE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners